Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | STAT1 | P42224 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1650997 | 0.80 | DYRK1A (0.60) | DYRK1ASMN1; SMN2PIK3CAPIK3CGPIK3CB | |
| SCHEMBL1653654 | 0.79 | SMN1; SMN2 (0.62) | DYRK1ASMN1; SMN2PIK3CAPIK3CGPIK3CB | |
| SCHEMBL1650409 | 0.78 | KMT2A (0.51) | DYRK1ASMN1; SMN2PIK3CAPIK3CGADORA1 | |
| SCHEMBL1651603 | 0.78 | DYRK1A (0.50) | DYRK1APIK3CAPIK3CGADORA1NPC1 | |
| SCHEMBL1650746 | 0.76 | PIK3CA (0.51) | DYRK1ASMN1; SMN2PIK3CAPIK3CGPIK3CB | |
| SCHEMBL1650388 | 0.75 | PIK3CA (0.49) | DYRK1APIK3CAPIK3CGPIK3CBADORA1 | |
| SCHEMBL1650546 | 0.74 | ALDH1A1 (0.58) | DYRK1ASMN1; SMN2PIK3CAPIK3CGPIK3CB | |
| SCHEMBL1651590 | 0.74 | PIK3CA (0.59) | DYRK1ASMN1; SMN2PIK3CAPIK3CGPIK3CB | |
| SCHEMBL1650938 | 0.73 | PIK3CA (0.51) | DYRK1APIK3CAPIK3CGADORA1 | |
| SCHEMBL1651318 | 0.73 | TP53 (0.44) | DYRK1APIK3CAPIK3CGPIK3CBADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
| WO-2010008847-A2 | PI3K/M TOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | MTOR, RICTOR, PIK3CA | DYRK1A 3783/4885SMN1; SMN2 4206/4885PIK3CA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.